While the applicability of the Immunome Discovery Engine is broad, Immunome’s focus is on the development of new therapies for oncology and infectious diseases.


Our primary focus areas are in the oncology and infectious disease spaces. We are leveraging the insights from the Immunome Discovery Engine to guide the discovery of future oncology pipeline assets and enable future strategic collaborations and additional value creation.


IMM-ONC-01 (IL-38)

Immunome’s lead oncology discovery program targets IL-38, a lesser-known member of the IL-1 family of cytokines. Data suggests that IL-38 is a novel immune checkpoint that allows tumors to evade the immune system response efforts. Some solid tumors, including those found in prostate, colorectal and lung cancers, over-express IL-38, resulting in low levels of tumor-infiltrating T cells, which are a hallmark of successful immune response. By blocking the IL-38 function with an antibody, Immunome believes it may be able to restore the immune response against the tumor, resulting in anti-tumor activity.

Functional Clusters

Our platform produces unique insights into the biology of cancer – uncovering a compelling picture as multiple non-canonical targets have accrued from our efforts. While there is often little information available on unique antigens, our data reveals a “functional clustering” of the targets to which cancer patients were mounting an immune response. In essence, these findings provide critical clues about the key methods by which each patient’s immune system fights back against their disease. These functional clusters may provide an important insight into the most important tumor-driven processes that should be attacked to overcome a disease threat.



Our platform is also being leveraged in the fight against COVID-19. The Immunome Discovery Engine is being used to interrogate the immune response of COVID-19 “super-responders”, individuals who have successfully fought the virus. We aim to isolate antibodies that initiate multiple viral clearance mechanisms simultaneously, like neutralization, complement fixation, and phagocytosis, among others. We will combine a mixture of these antibodies to develop a Biosynthetic Convalescent Plasma (BCP) that can be of potential use in both treatment and prophylactic settings. We are currently engaged in the research and development of an effective antibody mixture.

Select convalescent patients with strong anti-viral titer
Collect convalescent blood and isolate memory B cells
Deep repertoire screening against multiple viral proteins
Screen for anti-viral antibodies
Biosynthetic Convalescent Plasma for prophylaxis and treatment
Produce antibody mixture (up to 6 Abs) using recombinant manufacture